------------------------ Yahoo! Groups Sponsor --------------------~--> Get fast access to your favorite Yahoo! Groups. Make Yahoo! your home page http://us.click.yahoo.com/dpRU5A/wUILAA/yQLSAA/H4xqlB/TM --------------------------------------------------------------------~->
TVM Raises $290.8 Million (EUR 240.3 Million) for TVM Life Science Ventures VI; Fund to Focus on Biotech and Biopharmaceutical Investment Opportunities in the U.S. and Europe 10/5/2005 6:00:00 AM EST TVM, one of the leading life sciences and information technology venture capital firms in Europe and the United States, today announced the closing of its latest life sciences fund, TVM Life Science Ventures VI (TVM LSV VI). Committed capital totaled $290.8 million (EUR 240.3 million) and was raised from a broad mix of investors, including lead investors European Investment Fund (ERP- EIF Fund of Funds) and AlpInvest. About 20 other investors from Europe, the United States and Asia have invested in the new TVM fund, including KfWBankengruppe (Germany), Skandia Liv Asset Management (Sweden); Temasek Holdings Pte Ltd. (Singapore); Development Fund, Taiwan government's economic investment catalyst; and Quintiles Transnational Corp., the world's largest pharmaceutical services organization. Genzyme Corporation, and Biogen Idec, two of the most prominent global biotech companies headquartered in the U.S., also invested in TVM LSV VI. As with its previous funds, TVM LSV VI will maintain a strong emphasis on investments in the fields of drug discovery and development and will fund both early and late stage companies in the U.S. and Europe. The percentage of early and late stage companies will be market-driven, as TVM seeks to fund the best deals on both continents. The first two investments in the fund will be Newron Pharmaceuticals SpA and elbion AG. Newron Pharmaceuticals is a Milan-based spin-out of Pharmacia Upjohn, a late stage company engaged in the discovery and development of innovative CNS compounds in the area of neuroprotection, neurodegeneration and pain. Newron is currently in phase III clinical development in Parkinson's Disease and in phase II in neuropathic pain. elbion, located in Radebeul, Germany, is a developer of small molecule therapeutics, and TVM is investing in the company as part of the company's recently closed EUR 35 million financing. "The high quality of the investors in this fund is a testament to TVM's strong track record of identifying promising life sciences companies and supplying them with access to the scientific, capital and management resources critical for success," said Dr. Helmut M. Schuehsler, Managing Partner of TVM's Life Sciences practice. "One of our strategic goals is to build a larger presence in the U.S. biotech industry, as well as the emerging Asian market. Investments from Biogen Idec, Genzyme, Quintiles and the first European investment of Taiwan's Executive Yuan's Development Fund will help us to intensify our access to the important U.S. biotech market and to emerging markets in Asia." While it is important to continue financing and developing existing companies with advanced products to establish a top group of successful and internationally competitive firms in this sector, TVM also continues to see a great opportunity in early stage investing. Currently, valuations for biotech firms are favorable for new investors, enabling TVM to take a significant ownership position and actively participate in the development of its portfolio companies. As pharmaceutical giants increasingly look to biotechs to enhance their product pipelines, effective value enhancements of start-up companies with innovative products is becoming a more consistent reality. TVM's four-to-seven year investment time horizon and active participation in strategy and management gives its portfolio companies the best chance to capitalize on this opportunity. About TVM TVM, founded in 1983, is one of the first venture capital firms formed in Germany, and an early entrant into the U.S. market in 1986. Since inception TVM has raised more than EUR 1.4 billion in six fund generations and has established itself as a leading technology investment group in Europe and the United States. TVM funds have made investments in more than 220 information life science and technology companies where innovation, effective management and sound financial backing have enormous impact on company growth. The in-depth knowledge at TVM of the European and U.S. environment helps companies create businesses that enjoy access to science, management talent, distribution channels and capital on both sides of the Atlantic. More than 40 TVM companies went public at European or US stock exchanges. Today, TVM is actively invested in more than 70 companies. For more information please visit www.tvmvc.com http://www.arizonabiotech.com/ http://groups.yahoo.com/group/biotech-news/ http://www.arizonaentrepreneurs.com/ http://www.azhttp.com/ http://www.arizonabiotech.com/index.php http://www.mail-archive.com/biotech-news@yahoogroups.com/ http://www.mail-archive.com/biotech- [EMAIL PROTECTED]/maillist.html http://www.arizonabiotech.com/ <a href="http://www.arizonabiotech.com/";>Arizona Biotech</a> http://groups.yahoo.com/group/biotech-news/ <a href="http://groups.yahoo.com/group/biotech-news/";>Biotech News</a> http://www.arizonaentrepreneurs.com/ <a href="http://www.arizonaentrepreneurs.com/";>Arizona Entrepreneurs</a> http://www.azhttp.com/ <a href="http://www.azhttp.com/";>Arizona High Tech</a> Yahoo! Groups Links <*> To visit your group on the web, go to: http://groups.yahoo.com/group/biotech-news/ <*> To unsubscribe from this group, send an email to: [EMAIL PROTECTED] <*> Your use of Yahoo! Groups is subject to: http://docs.yahoo.com/info/terms/
